Veru Inc. (VERU): Price and Financial Metrics

Veru Inc. (VERU): $0.94

0.03 (+3.23%)

POWR Rating

Component Grades








VERU Price/Volume Stats

Current price $0.94 52-week high $6.57
Prev. close $0.92 52-week low $0.66
Day low $0.89 Volume 415,502
Day high $0.95 Avg. volume 1,711,688
50-day MA $0.89 Dividend yield N/A
200-day MA $1.32 Market Cap 85.28M

VERU Stock Price Chart Interactive Chart >


  • VERU scores best on the Growth dimension, with a Growth rank ahead of 76.17% of US stocks.
  • The strongest trend for VERU is in Growth, which has been heading up over the past 177 days.
  • VERU's current lowest rank is in the Stability metric (where it is better than 2.96% of US stocks).

VERU Stock Summary

  • In terms of twelve month growth in earnings before interest and taxes, VERU INC is reporting a growth rate of 152.86%; that's higher than 92.32% of US stocks.
  • As for revenue growth, note that VERU's revenue has grown -71.34% over the past 12 months; that beats the revenue growth of just 2.7% of US companies in our set.
  • In terms of volatility of its share price, VERU is more volatile than 95.07% of stocks we're observing.
  • Stocks with similar financial metrics, market capitalization, and price volatility to VERU INC are IMNM, YMAB, GNTX, VYNE, and PXLW.
  • Visit VERU's SEC page to see the company's official filings. To visit the company's web site, go to

VERU Valuation Summary

  • In comparison to the median Healthcare stock, VERU's price/earnings ratio is 103.29% lower, now standing at -0.8.
  • Over the past 243 months, VERU's price/sales ratio has gone up 1.6.

Below are key valuation metrics over time for VERU.

Stock Date P/S P/B P/E EV/EBIT
VERU 2023-11-03 6.0 2.6 -0.8 -0.7
VERU 2023-11-02 5.9 2.6 -0.8 -0.7
VERU 2023-11-01 5.2 2.3 -0.7 -0.6
VERU 2023-10-31 5.4 2.4 -0.7 -0.7
VERU 2023-10-30 5.7 2.5 -0.8 -0.7
VERU 2023-10-27 5.3 2.3 -0.7 -0.6

VERU Growth Metrics

    Its 3 year revenue growth rate is now at 151.39%.
  • The 5 year revenue growth rate now stands at 163.84%.
  • Its year over year net income to common stockholders growth rate is now at -5684.31%.
Over the past 52 months, VERU's revenue has gone up $11,862,531.

The table below shows VERU's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 27.72701 -73.38124 -114.2382
2022-09-30 39.35435 -47.505 -83.77602
2022-06-30 52.41218 -27.43297 -47.04789
2022-03-31 60.46558 -26.24523 -27.54518
2021-12-31 60.77767 -24.88806 -16.21333
2021-09-30 61.25953 -15.57102 7.394374

VERU's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • VERU has a Quality Grade of C, ranking ahead of 60.52% of graded US stocks.
  • VERU's asset turnover comes in at 0.473 -- ranking 93rd of 681 Pharmaceutical Products stocks.
  • INSM, MNKD, and REPH are the stocks whose asset turnover ratios are most correlated with VERU.

The table below shows VERU's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.473 0.788 0.038
2021-03-31 0.540 0.756 0.193
2020-12-31 0.760 0.737 0.295
2020-09-30 0.750 0.723 -0.912
2020-06-30 0.691 0.684 -0.376
2020-03-31 0.716 0.696 -0.365

VERU Price Target

For more insight on analysts targets of VERU, see our VERU price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $24.40 Average Broker Recommendation 1.3 (Strong Buy)

Veru Inc. (VERU) Company Bio

Veru Inc. operates as a urology and oncology biopharmaceutical company. The company operates through two segments, Commercial; and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation. The company's urology drug candidates include Tamsulosin delayed release sachet and Tamsulosin XR capsules that are under bioequivalence study for the treatment of benign prostatic hyperplasia; and Solifenacin delayed release granules, which are under bioequivalence study for the treatment of overactive bladder. Its urology drug candidates also comprise Tadalafil-Finasteride combination capsules that are under bioequivalence study for the treatment of men with lower urinary tract symptoms and enlarged prostate; VERU-944, which is in Phase II clinical trial for the treatment of hot flashes in men on prostate cancer hormonal therapies; and VERU-722 that is in Phase II clinical trial for the treatment of male infertility caused by testicular dysfunction. The company's oncology drug candidate is VERU-111, a novel oral alpha and beta tubulin inhibitor, which is under preclinical study for the treatment of metastatic prostate, breast, endometrial, ovarian, and other cancers. It also develops VERU-111/VERU-112, a novel oral agent targeting colchicine binding site that is under preclinical study for the treatment of gout and familial mediterranean fever. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was founded in 1896 and is based in Miami, Florida.

VERU Latest News Stream

Event/Time News Detail
Loading, please wait...

VERU Latest Social Stream

Loading social stream, please wait...

View Full VERU Social Stream

Latest VERU News From Around the Web

Below are the latest news stories about VERU INC that investors may wish to consider to help them evaluate VERU as an investment opportunity.

The past year for Veru (NASDAQ:VERU) investors has not been profitable

The art and science of stock market investing requires a tolerance for losing money on some of the shares you buy. But...

Yahoo | November 10, 2023

Verano Holdings Corp. (VRNOF) Reports Q3 Loss, Lags Revenue Estimates

Verano Holdings Corp. (VRNOF) delivered earnings and revenue surprises of 0% and 0.01%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 8, 2023

Veru Reports Muscle Data from 5 Clinical Studies of Enobosarm that Support the Advancement of Enobosarm in Combination with Weight-Loss GLP-1 Drugs, Ozempic®, Wegovy®, or Mounjaro®, to Optimize Weight Loss by Preventing Muscle Wasting and Further Increasing Fat Loss in a Phase 2b Obesity Clinical Study

-- In 5 clinical studies involving 968 older men and postmenopausal women with and without muscle wasting, enobosarm has demonstrated the ability to decrease fat mass, increase muscle mass, and improve muscle strength and physical function -- -- Weight-loss drugs like Ozempic, Wegovy, Mounjaro and other GLP-1 drugs cause a significant loss of both fat and muscle; in older obese or overweight patients who may already have low muscle mass, the further drop in muscle mass of all-important muscles i

Yahoo | October 4, 2023

Veru Reaches Agreement with FDA on New Phase 3 Clinical Trial for Sabizabulin for Broader Indication: Hospitalized Adult Patients with Any Type of Viral Acute Respiratory Distress Syndrome (ARDS)

--Reached agreement with FDA on single Phase 3 clinical trial design to expand treatment population to include all hospitalized adult patients with any type of virus induced ARDS including the “tripledemic viruses”: Influenza, RSV, and SARS-CoV-2-- -- Based on high mortality rate for viral ARDS, expected sabizabulin Phase 3 study size is 408 patients with all-cause mortality at Day 60 as the primary endpoint-- --The Company plans to conduct the “all comers” viral ARDS Phase 3 study instead of th

Yahoo | September 26, 2023

Veru to Participate in Fireside Chat at the 2023 Cantor Fitzgerald Global Healthcare Conference on September 28th, 2023

MIAMI, FL, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for metastatic breast cancer and for viral induced acute respiratory distress syndrome (ARDS), today announced that Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru, will participate in a fireside chat at the 2023 Cantor Fitzgerald Global Healthcare Conference to be held at the InterContinental New York, Barcl

Yahoo | September 20, 2023

Read More 'VERU' Stories Here

VERU Price Returns

1-mo 4.11%
3-mo -9.62%
6-mo -9.62%
1-year -83.45%
3-year -69.08%
5-year -37.33%
YTD -82.20%
2022 -10.36%
2021 -31.91%
2020 158.21%
2019 139.29%
2018 22.81%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!